Sulkowski S, Ejsmont-Pietrow G, Musiatowicz B, Sulkowska M
Zakładu Anatomii Patologicznej AM, Białymstoku.
Pneumonol Alergol Pol. 1993;61(11-12):574-8.
Pentoxifylline (3,7-dimethyl-1-/5-oxohexyl)-xanthine (PTXF) is a drug that has been demonstrated to improve peripheral vascular circulation. The mechanism of this effect is believed to involve the prevention of platelet aggregation, reduction of blood viscosity and increase red blood cell flexibility. PTXF has been successfully used as a therapeutic agent for intermittent claudication secondary to chronic occlusive arterial disease. In the present paper, the special attention was paid to the possibility of using PTXF in the treatment of ARDS and PTXF mechanisms of action preventing the development of that syndrome were reviewed.
己酮可可碱(3,7 - 二甲基 - 1 - /5 - 氧代己基) - 黄嘌呤(PTXF)是一种已被证明能改善外周血管循环的药物。据信这种作用机制涉及预防血小板聚集、降低血液粘度和增加红细胞柔韧性。PTXF已成功用作治疗慢性闭塞性动脉疾病继发间歇性跛行的治疗剂。在本文中,特别关注了使用PTXF治疗急性呼吸窘迫综合征(ARDS)的可能性,并综述了PTXF预防该综合征发生的作用机制。